Combined use of acid fibroblast growth factor, granulocyte colony stimulating factor
and zinc sulphate accelerate diabetic ulcer healing.
has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), a scientific panel of the European Medicines Agency (EMEA), for its human granulocyte colony stimulating factor
The RECOVER trial, which explored the idea of using granulocyte colony stimulating factor
(GCSF) to increase the level of circulating stem cells in patients shortly after heart attacks with significant heart damage, failed to achieve its goal.
Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction using granulocyte colony stimulating factor
Next, all patients will receive granulocyte colony stimulating factor
to mobilize the hematopoietic (blood forming) CD34+ cells from their bone marrow to their blood stream.
(TSX: DDD; OTC BB: DRUG), Vancouver, has entered into an agreement with Suzhou Zhongkai Bio-Pharmaceuticals Company Limited ("Zhongkai") to in-license the exclusive right to commercialize its Recombinant Human Granulocyte Colony Stimulating Factor
("rhG- CSF") product worldwide, excluding the People's Republic of China.
The drug, a bioengineered form of a natural protein called granulocyte colony stimulating factor
, is already used by people who've donated marrow to others and by cancer patients.
Current regimens include half-dose chemotherapeutic agents such as methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) with adjunctive use of hematopoietic growth factor (granulocyte-macrophage colony stimulating factor, GM-CSF, or granulocyte colony stimulating factor
, G-CSF).[14,15] However, complete response occurs in ~65% of treated patients, with relapse in ~25% of these patients within 6 months.
A role for G-CSF (granulocyte colony stimulating factor
) in the central nervous system.
At the same time, Stem Cell announced that it has received a patent in Japan for the use of granulocyte colony stimulating factor
(GM-CSF) to treat white matter disorders, such as Multiple Sclerosis, Acute Disseminating Encephalomyelitis, Diffuse Cerebral Sclerosis, etc, by bolstering the number of stem cells available to form CNS oligodendrocytes.